- Home
- ALGS vs LUNG Comparison
ALGS vs LUNG Comparison
Compare ALGS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | LUNG |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.2M | 72.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALGS | LUNG |
|---|---|---|
| Price | $8.19 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $46.67 | $6.81 |
| AVG Volume (30 Days) | 79.7K | ★ 348.8K |
| Earning Date | 03-09-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,646,000.00 | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $3.76 | $1.31 |
| 52 Week High | $30.02 | $9.37 |
Technical Indicators
Market Signals| Indicator | ALGS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 37.89 |
| Support Level | $7.92 | $1.68 |
| Resistance Level | $9.13 | $1.92 |
| Average True Range (ATR) | 0.91 | 0.11 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 15.97 | 15.40 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.